AzTrials
AzTrials

Diabetes Mellitus, Type 2NCT04041492

Effect of Vitamins D3 and K2 in uOc and Insulin Serum Levels in Patients With Diabetes Mellitus

A study testing Supplementation with Vitamin D3 y K2 in people with Diabetes Mellitus, Type 2 and Bone Loss, run by University of Guadalajara at 1 site in Mexico.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Introduction: Patients with DM2 have chronic hyperglycemia derived from a decrease in insulin sensitivity, cause of comorbidities such as bone demineralization, decreasing quality of life and increasing mortality. Read more about this study

Who is it for?
Ages 30 to 75 years
What is being tested?
Supplementation with Vitamin D3 y K2
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
100 participants
Where
1 siteMexico
Study dates
14 Feb 2017to 14 Feb 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 30 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Originating and residents of Western Mexico
  • Both genres
  • Age of 30-75 years
  • Diagnosis of DM2 (ADA Criteria) of at least 5 years of evolution
  • Sign an informed consent letter.

Who cannot join

  • Use of active drugs for bone mineralization
  • Pregnancy
  • Lactation
  • Creatinine or transaminase more than double the upper limit
  • Diet added with calcium or vitamins (D, K).

Trial locations and contacts

1 site in 1 country.

Mexico1 site
  • Julio Iván Aguayo

    Guadalajara, Jalisco, 44730

Other trials in Mexico

About this study

Official title: Effect of Supplementation With Vitamins D3 and K2 in Non-carboxyled Osteocalcine and Insulin Serum Levels in Patients With Diabetes Mellitus Type 2

Introduction: Patients with DM2 have chronic hyperglycemia derived from a decrease in insulin sensitivity, cause of comorbidities such as bone demineralization, decreasing quality of life and increasing mortality. This could be related to changes in the serum levels of carboxylated Osteocalcin and Insulin, together with the deficit the daily consumption of vitamins D3 and K, which is crucial for the process of mineralization of the bone matrix.

Research question: What is the effect of supplementation with Vitamins D3 and K2 on serum levels of Carboxylated Osteocalcin and Insulin in patients with Type 2 Diabetes mellitus?

Read more

Hypothesis: Supplementation with Vitamins D3 and K2 modifies the serum levels of Carboxylated Osteocalcin and Insulin in patients with Type 2 Diabetes mellitus.

General Objectives: To assess the effect of supplementation with Vitamins D3 and K2 on serum levels of Carboxylated and Non-Carboxylated Osteocalcin in patients with Type 2 Diabetes mellitus.

Material and Methods: Clinical trial, double blind, randomization, 40 patients with DM2, 35-65 years, supplementation (3 months), clinical and laboratory determinations (uOC and Insulin).

  • Group 1: Vitamin D3 1000UI + Placebo
  • Group 2: Vitamin K2 100 mcg + Placebo
  • Group 3 (Positive Control): Vitamins D3 1000UI + K2 100 mcg
Read the detailed description

Type 2 diabetes mellitus is a group of metabolic disorders characterized by chronic hyperglycemia, being one of the main causes of mortality in our country.

There are different comorbidities, including bone demineralization, which involve an imbalance in the process of bone formation and resorption, which entails the risk of decreasing bone mineral density. These processes could be related to the serum levels of Non-carboxylated Osteocalcin and Insulin, said molecule locally modulates the process of bone mineralization.

On the other hand, it is known that the daily consumption of vitamins in a general diet in our population (specifically including vitamins D3 and K), is below the necessary basic requirements, so considering crucial elements for the benefit of Bone matrix mineralization, which is why the present study proposes supplementation with the aforementioned vitamins in patients with Type 2 DM, to avoid a decrease in bone mineral density, increasing the mortality rate of individuals suffering from it.

  1. - The study subjects from the West of the country were invited to participate in the research protocol, where their objective was explained and the signing of the consent was requested under information, where a structured evaluation was subsequently carried out consisting of :
  2. Comprehensive clinical evaluation (including general sociodemographic data of a complete medical history).
  3. - Once the previous data was obtained, the randomization of the treatment was carried out, classifying the patients in the following groups:
  • Group 1 Vitamin D3 1000UI + Placebo (Calcined Magnesia).
  • Group 2 Vitamin K2 100 mcg + Placebo (Calcined Magnesia).
  • Group 3 (Positive Control) Vitamins D3 1000UI + K2 100 mcg.
  1. - Blood sample collection through Punzocat, which was placed in a red tube, for subsequent centrifugation at 3500rpm x 15 minutes, performing aliquots of the serum obtained and stored at -80 ° C and thus perform the pertinent quantifications of the molecules to study.
  2. - Quantification of serum levels of non-carboxylated Osteocalcin and Insulin
  3. The determinations corresponding to the serum levels of Non-carboxylated Osteocalcin and Insulin were made, both baseline prior to the intervention as well as the final quantification, once the supplementation was finished, by means of the indirect ELISA technique (commercial reagents -Takara were used - for the realization of these determinations), which involved the following process: In a plate the wells were coated with a first antibody, then a wash was performed to remove the excess antibody, after that, the sample in which the antigen was found was added, which was retained in the well after being recognized by the first antibody, a second wash was subsequently made to remove unbound material, then a solution with a second labeled anti-antigen antibody was applied. Thus each antigen molecule was bound to an antibody in the base that kept it fixed and a second antibody for its reaction and labeling. Finally, the plate was introduced into a spectophotometer and the absorbance was measured at a length of 450 nm, for both non-carboxylated Osteocalcin and Insulin.
  4. - The quantification in serum of cholesterol and triglycerides was carried out by using the fully automated random access analyzer equipment for clinical chemistry, model ERBA XL 200.
  5. - The evaluation of the HOMA index was calculated by using the equations HOMA-IR and HOMA-B, for insulin resistance (IR) and Percentage, respectively.
  6. - The daily of adherence to treatment was provided, so that they recorded all those important events that would ensure adequate intake of vitamins, as well as adverse reactions to them, which were evaluated in scheduled appointments, in addition to each The corresponding bottles were delivered consecutively for each of the 3 months of intervention, with the corresponding vitamins for each patient according to their allocation group.
  7. - Finally, in the last visit the results obtained during the whole study were made known to each of the patients.
Being tested
Supplementation with Vitamin D3 y K2
Keywords
diabetes, osteocalcin, insulin
Medical subject headings
Diabetes Mellitus, Type 2, Bone Diseases, Metabolic, Insulin Resistance, Diabetes Mellitus

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Supplementation with Vitamin D3 y K2Dietary supplement

    Supplementation at a dose of 1 capsule every 24 hours x 3 months

Study groups in NCT04041492
Study groupRoleWhat they receive
Group 1ExperimentalVitamin D3 1000UI + Placebo (Calcined Magnesia).
Receives: Dietary Supplement: Supplementation with Vitamin D3 y K2
Group 2ExperimentalVitamin K2 100 mcg + Placebo (Calcined Magnesia).
Receives: Dietary Supplement: Supplementation with Vitamin D3 y K2
Group 3Active comparatorVitamin D3 1000UI + Vitamin K2 100 mcg
Receives: Dietary Supplement: Supplementation with Vitamin D3 y K2

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Non-carboxylated osteocalcin

    Serum levels

    Measured: 3 months

  2. Insulin

    Serum levels

    Measured: 3 months

Secondary outcomes (4)
  1. Weight

    kg

    Measured: 3 months

  2. Height

    m

    Measured: 3 months

  3. Body mass index

    Quetelet index

    Measured: 3 months

  4. HOMA Index

    Insulin resistance

    Measured: 3 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Aug 2019
  2. Study start14 Feb 2017
  3. Primary completion14 Feb 2018
  4. Study completion14 Feb 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Single group
Model description
Controlled clinical trial, with randomization simple, double blind.
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
100 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04041492
Sponsor's protocol ID
F-2017-1702-14
Status last verified
Jul 2019
First submitted
31 Jul 2019
Last updated
2 Aug 2019
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Non-sharable data

Publications

  • Salinas-Varela Y, Barajas-Gonzalez MA, Martinez-Lopez E, Llamas-Covarrubias IM, Lopez-Quintero A, Sanchez-Enriquez S, Rivera-Leon EA. Association between the VKORC1 rs8050894 CC genotype and undercarboxylated osteocalcin levels following vitamin K and D supplementation in Mexican Citizens with T2DM: A randomized clinical trial. J Investig Med. 2026 Jun 8:10815589261460882. doi: 10.1177/10815589261460882. Online ahead of print.

    PubMed 42257367
  • Aguayo-Ruiz JI, Garcia-Cobian TA, Pascoe-Gonzalez S, Sanchez-Enriquez S, Llamas-Covarrubias IM, Garcia-Iglesias T, Lopez-Quintero A, Llamas-Covarrubias MA, Trujillo-Quiroz J, Rivera-Leon EA. Effect of supplementation with vitamins D3 and K2 on undercarboxylated osteocalcin and insulin serum levels in patients with type 2 diabetes mellitus: a randomized, double-blind, clinical trial. Diabetol Metab Syndr. 2020 Aug 18;12:73. doi: 10.1186/s13098-020-00580-w. eCollection 2020.

    PubMed 32831908

Questions about this trial

What is this clinical trial studying?

A study testing Supplementation with Vitamin D3 y K2 in people with Diabetes Mellitus, Type 2 and Bone Loss, run by University of Guadalajara at 1 site in Mexico.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 Aug 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Mexico. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Non-carboxylated osteocalcin (time frame: 3 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04041492, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Aug 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in